Compare Eli Lilly And Co (LLY) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Norfolk Southern Corporation — how do they compare? Eli Lilly And Co trades at $1,177.1 (market cap $1.04T), while Norfolk Southern Corporation trades at $317.62 (market cap $71.20B). The key difference: Eli Lilly And Co is far larger — about 14.6× Norfolk Southern Corporation's market cap, and Norfolk Southern Corporation pays the higher dividend (1.7%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Norfolk Southern Corporation for 33 Days on average.
| LLY | NSC | |
|---|---|---|
Market Cap | $1.04T | $71.20B |
Volume | 3,064,878 | 555,248 |
Sector | Health | Industrials |
52-Week High | $1.28K | $352.98 |
52-Week Low | $799.57 | $278.19 |
Typical Hold Time | 93 Days | 33 Days |
Enterprise Value | $1.09T | $86.75B |
Dividend Yield | 0.59% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Norfolk Southern (NSC) trades at $317.67, up 1.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with a strong net income margin of 21.02% (2026). Positive sentiment surrounds the proposed merger with Union Pacific, which is advancing through regulatory review and is backed by over 500 customers, as reported by Business Wire on September 22, 2026.
The outlook is positive, with a consensus price target of $361.86 offering ~14% upside. Key opportunities include freight share gains from trucking and merger synergies, while risks involve fuel price pressures on margins and regulatory hurdles for the combination. Earnings on October 22, 2026, will be a critical catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
